AMAG Pharmaceuticals Earnings: Here’s Why Investors Like These Results
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had a loss and beat Wall Street’s expectations, AND met the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are up 3.72%.
AMAG Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.18 in the quarter versus EPS of $-0.58 in the year-earlier quarter.
Revenue: Rose 15.63% to $17.9 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: AMAG Pharmaceuticals, Inc. reported adjusted EPS loss of $0.18 per share. By that measure, the company beat the mean analyst estimate of $-0.21. It met the average revenue estimate of $17.9 million.
Quoting Management: “We have gotten off to a very strong start in 2013, delivering record results through a combination of solid top-line growth and disciplined financial management,” said William Heiden, president and chief executive officer of AMAG. “In the first quarter, we achieved our largest volume of non-dialysis Feraheme sales since launch. Our new chief commercial officer, Greg Madison, and his team did an excellent job of driving Feraheme performance this quarter, achieving especially strong growth in the largest segment of the non-dialysis IV iron market, the hospital segment.”
Key Stats (on next page)…
Revenue decreased 15.33% from $21.14 million in the previous quarter. EPS decreased to $-0.18 in the quarter versus EPS of $-0.17 in the previous quarter.
Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.2 to a loss $0.16. For the current year, the average estimate has moved up from a loss of $0.71 to a loss of $0.69 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)